USANA Health Sciences, Inc. (NYSE:USNA) CEO Sells $147,350.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) CEO Jim Brown sold 5,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

USANA Health Sciences Stock Performance

NYSE USNA opened at $29.97 on Tuesday. USANA Health Sciences, Inc. has a one year low of $27.71 and a one year high of $50.32. The stock has a 50-day moving average of $33.42 and a 200 day moving average of $36.47. The company has a market capitalization of $571.21 million, a price-to-earnings ratio of 10.59, a PEG ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, equities analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

USNA has been the subject of several research analyst reports. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. Finally, Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of USNA. Pacer Advisors Inc. boosted its position in USANA Health Sciences by 16.5% in the third quarter. Pacer Advisors Inc. now owns 544,256 shares of the company’s stock worth $20,638,000 after purchasing an additional 76,904 shares during the last quarter. Pzena Investment Management LLC boosted its position in USANA Health Sciences by 7.5% in the third quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company’s stock worth $39,801,000 after purchasing an additional 72,977 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in USANA Health Sciences by 7.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock worth $27,751,000 after purchasing an additional 55,059 shares during the last quarter. Jane Street Group LLC boosted its position in USANA Health Sciences by 330.0% in the fourth quarter. Jane Street Group LLC now owns 39,979 shares of the company’s stock worth $1,435,000 after purchasing an additional 30,681 shares during the last quarter. Finally, Norges Bank purchased a new position in USANA Health Sciences in the fourth quarter worth about $953,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.